Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 807-111-0 | CAS number: 1211441-98-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Compared with the Cmax and AUC(0-72h) values at 100 mg/kg, the Cmax and AUC(0-72h) values
measured in the female dog at 150 mg/kg were slightly lower. This was mostly due to
vomiting with dose formulation resulting in lower uptake of the test item.
In conclusion, oral administration of single dosages of LEE011 at 25, 50, 100 and 150 mg/kg
to one male and one female Beagle dogs was well tolerated up to 25 (males) and 50 mg/kg
(females). Based on the slight to severe decreases in food consumption at ≥ 25 mg/kg and the
toxicokinetic parameters, a no-observable-effect-level (NOEL) was not established in this
study, whereas a single dose of 100 mg/kg LEE011 was considered to be the maximum
tolerable dose (MTD) in view of the pronounced emesis at ≥ 100 mg/kg.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Justification for type of information:
- This non-GLP study has been performed to the highest standards of scientific quality in
accordance with our Standard Operating Procedures. With the exception of inspections by
Quality Assurance and of a report audit, this study was conducted according to the basic
applicable requirements of GLP in Switzerland. - Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- The succinate salt of LEE011 (batch no. 0850001) was administered as single dosages of 25,
50, 100 and 150 mg/kg to Beagle dogs of 7.5 to 9.7 kg and 12 to 13 months of
age at start of dosing. The dose formulation was a suspension in a 0.5 % methylcellulose
aqueous solution w/v, (MC, low viscosity, M0430) using Nanopure water. - GLP compliance:
- no
- Remarks:
- Study has been performed to the highest standards of scientific quality in accordance with our Standard Operating Procedures. With the exception of inspections by QA, this study was conducted according to the requirements of GLP in Switzerland.
- Species:
- dog
- Strain:
- other: Beagle dogs
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Beagle dogs of 7.5 to 9.7 kg and 12 to 13 months of age
- Route of administration:
- oral: gavage
- Vehicle:
- methylcellulose
- Details on oral exposure:
- The succinate salt of LEE011 (batch no. 0850001) was administered as single dosages of 25,
50, 100 and 150 mg/kg to Beagle dogs of 7.5 to 9.7 kg and 12 to 13 months of
age at start of dosing. The dose formulation was a suspension in a 0.5 % methylcellulose
aqueous solution w/v, (MC, low viscosity, M0430) using Nanopure water. - Doses:
- Dosing days Dose Dosage volume Test item concentration No. of Animal no.
(mg/kg)* (ml/kg) (mg/ml)* animals /Sex
1 25 (31.8) 2 12.5 (15.9) 2 42M, 41F
7 50 (63.6) 2 25 (31.8) 2 42M, 41F
10 100 (127.2) 2 50 (63.6) 2 44M, 43F
15 150 (190.8) 2 75 (95.4) 2 44M, 43F
* Expressed in terms of the base. Equivalent dosages expressed in terms of the salt are given in parentheses (salt/base ratio: 1.272).
The following investigations were performed: mortality, clinical signs, body weight and food consumption. Blood was collected for toxicokinetics on each day of dosing at predose, 0.5, 1, 3, 7, 24, 48 and 72 hours postdose. - No. of animals per sex per dose:
- Dosing days Dose Dosage volume Test item concentration No. of Animal no.
(mg/kg)* (ml/kg) (mg/ml)* animals /Sex
1 25 (31.8) 2 12.5 (15.9) 2 42M, 41F
7 50 (63.6) 2 25 (31.8) 2 42M, 41F
10 100 (127.2) 2 50 (63.6) 2 44M, 43F
15 150 (190.8) 2 75 (95.4) 2 44M, 43F
* Expressed in terms of the base. Equivalent dosages expressed in terms of the salt are given in parentheses (salt/base ratio: 1.272).
The following investigations were performed: mortality, clinical signs, body weight and food consumption. Blood was collected for toxicokinetics on each day of dosing at predose, 0.5, 1, 3, 7, 24, 48 and 72 hours postdose. - Control animals:
- no
- Details on study design:
- The test item LEE011 (also referred to as ‘test article’) is a CDK4/6 (D-type cyclin-dependent
kinase) inhibitor. The purpose of this toxicity study in dogs was to establish the maximum
tolerable dose level of LEE011 after single administration to aid in the selection of
appropriate dose levels for a subsequent telemetry study.
The succinate salt of LEE011 (batch no. 0850001) was administered as single dosages of 25,
50, 100 and 150 mg/kg to Beagle dogs of 7.5 to 9.7 kg and 12 to 13 months of
age at start of dosing. The dose formulation was a suspension in a 0.5 % methylcellulose
aqueous solution w/v, (MC, low viscosity, M0430) using Nanopure water.
The following investigations were performed: mortality, clinical signs, body weight and food
consumption. Blood was collected for toxicokinetics on each day of dosing at predose, 0.5, 1,
3, 7, 24, 48 and 72 hours postdose. - Key result
- Sex:
- male/female
- Dose descriptor:
- other: maximum tolerable dose (MTD)
- Effect level:
- 100 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: no-observable-effect-level was not established in this study
- Mortality:
- No mortality occurred.
- Clinical signs:
- other: The main treatment-related clinical sign was dose-dependent emesis with dose formulation and mucus at ≥ 50 mg/kg in males and at ≥ 100 mg/kg in females. Frequency and intensity increased in a dose-dependent manner. At 100 mg/kg, both the male and female s
- Other findings:
- Food consumption:
Slight to severe decreases in food consumption were observed on days of dosing up to 4 days
postdose at ≥ 25 mg/kg. There was no clear dose dependency and overall food consumption
showed moderate to high variability including during pretest. - Interpretation of results:
- study cannot be used for classification
- Conclusions:
- Compared with the Cmax and AUC(0-72h) values at 100 mg/kg, the Cmax and AUC(0-72h) values
measured in the female dog at 150 mg/kg were slightly lower. This was mostly due to
vomiting with dose formulation resulting in lower uptake of the test item.
In conclusion, oral administration of single dosages of LEE011 at 25, 50, 100 and 150 mg/kg
to one male and one female Beagle dogs was well tolerated up to 25 (males) and 50 mg/kg
(females). Based on the slight to severe decreases in food consumption at ≥ 25 mg/kg and the
toxicokinetic parameters, a no-observable-effect-level (NOEL) was not established in this
study, whereas a single dose of 100 mg/kg LEE011 was considered to be the maximum
tolerable dose (MTD) in view of the pronounced emesis at ≥ 100 mg/kg.
Reference
Toxicokinetics
All animals (1 dog per sex per dose) receiving LEE011 were exposed to the parent drug with
the individual time to reach the highest plasma concentration (Tmax) generally observed
between 0.5-7 h postdose regardless of the dose.
For LEE011 and LEQ803 the exposure in general increased with increasing dose in an underproportional
manner in terms of AUC over the dosing regimen.
No clear conclusion on gender difference based on the exposure data could be made in view
of the low number of animals investigated.
The percentage of LEQ803 compared with LEE011 based on AUC(0-72h) was between 5-14 %.
Positive values were measured for time point 0 h in some profiles due to insufficient wash-out
period following the previous dose applied to the respective dogs. However, the positive 0 h
values accounts for 0.04-0.1 % for LEE011 and 0.4-0.9 % for LEQ803 when compared with
the corresponding Cmax. Therefore, the impact of the positive 0 h values on the results is
negligible.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
Single dose toxicity study (Dogs), Route of administration: Oral, 25 mg/kg, 50 mg/kg, 100 mg/kg, 150 mg/kg,
showed that the substance was:
- Well tolerated at 25 (males) and 50 mg/kg (females).
- The main treatment-related clinical sign was dose-dependent emesis of the dose formulation and mucus.
- The MTD was 100 mg/kg.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.